
Genetic testing company 23andMe Holding Co. (NASDAQ:ME) took the unconventional route of a SPAC deal to go public, and the stock hasn't gained much traction since it began trading on June 17, 2021.
The new year saw the company announcing its diversification into drug development. Will this pivot help a reversal in fortunes?